



UNIVERSITY OF LEEDS

This is a repository copy of *A Phase II Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-Positive Pathogens*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/119666/>

Version: Accepted Version

Article:

Huang, DB, File, TM, Torres, A et al. (5 more authors) (2017) A Phase II Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-Positive Pathogens. *Clinical Therapeutics*, 39 (8). pp. 1706-1718. ISSN 0149-2918

<https://doi.org/10.1016/j.clinthera.2017.07.007>

© 2017 Elsevier Inc. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

1 Table 1: Baseline and demographic characteristics among the ITT population by treatment

2

Characteristics	Iclaprim q12h* (n=23)	Iclaprim q8h** (n=24)	Vancomycin (n=23)
Age, mean years (SD)	62.9 (14.2)	58.8 (18.1)	62.7 (17.6)
Race, White, n (%)	23 (100)	24 (100)	23 (100)
Gender, n (%)			
Female	10 (43.5)	7 (29.2)	3 (13.0)
Male	13 (56.5)	17 (70.8)	20 (87.0)
Comorbidities, n (%)			
Diabetes	5 (21.7)	2 (8.3)	5 (21.7)
Cardiovascular disease	16 (69.6)	14 (58.3)	16 (69.6)
COPD	5 (21.7)	4 (16.7)	5 (21.7)
Renal failure	3 (13.0)	2 (8.3)	2 (8.7)
CPIS, mean (SD)	8.7 (1.2)	8.4 (1.3)	8.2 (1.1)
Chest X-ray Infiltrates, n (%)			
Localized	21 (91.3%)	19 (79.2%)	17 (73.9%)
Patchy or diffuse	2 (8.7%)	5 (20.8%)	6 (26.1)
Fever (oral temperature >38°C/100.4°F), n (%)	21 (91.3%)	21 (87.5%)	21 (91.3%)
Leukocytes (per mm ³) <4,000 or >11,000, n (%)	14 (60.9%)	12 (50.0%)	14 (60.9%)
PaO ₂ /FIO ₂ (mmHg)			
≤240 and no evidence of	11 (47.8%)	8 (33.3%)	6 (26.1%)

ARDS, n (%)			
>240 or ARDS, n (%)	12 (52.2%)	16 (66.7%)	17 (63.9%)
Baseline Microbiology, n (%)			
Exclusively Gram-positive pathogens	14 (60.9%)	11 (45.8%)	11 (47.8%)
Mixed Gram-positive and Gram-negative	9 (39.1%)	13 (54.2%)	12 (52.2%)
Concomitant aztreonam use, n (%)	9 (39.1%)	14 (58.3%)	<u>139</u> (<u>56.539</u> %)

3 ARDS = acute respiratory distress syndrome

4 *Iclaprim 0.8 mg/kg IV q12h

5 **Iclaprim 1.2 mg/kg IV q8h